CA2492781A1 - Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine - Google Patents

Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine Download PDF

Info

Publication number
CA2492781A1
CA2492781A1 CA002492781A CA2492781A CA2492781A1 CA 2492781 A1 CA2492781 A1 CA 2492781A1 CA 002492781 A CA002492781 A CA 002492781A CA 2492781 A CA2492781 A CA 2492781A CA 2492781 A1 CA2492781 A1 CA 2492781A1
Authority
CA
Canada
Prior art keywords
hmg
disease
coa reductase
pyridoxine
reductase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002492781A
Other languages
English (en)
Inventor
Tatsuhito Kondo
Ikuo Takagi
Masato Nakayama
Yasuhiro Torizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2492781A1 publication Critical patent/CA2492781A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un médicament non toxique destiné à réduire le taux de lipides sanguins et le taux d'homocystéine sanguine. Il se présente sous la forme d'une composition médicale contenant un inhibiteur de réductase HMG-CoA et un composé de pyridoxine.
CA002492781A 2002-07-11 2003-07-08 Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine Abandoned CA2492781A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002-202121 2002-07-11
JP2002202121 2002-07-11
JP2002343586 2002-11-27
JP2002-343586 2002-11-27
PCT/JP2003/008674 WO2004006919A1 (fr) 2002-07-11 2003-07-08 Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine

Publications (1)

Publication Number Publication Date
CA2492781A1 true CA2492781A1 (fr) 2004-01-22

Family

ID=30117429

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002492781A Abandoned CA2492781A1 (fr) 2002-07-11 2003-07-08 Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine

Country Status (7)

Country Link
JP (1) JP2010077162A (fr)
CN (1) CN100341509C (fr)
AU (1) AU2003281176A1 (fr)
CA (1) CA2492781A1 (fr)
HK (1) HK1077232A1 (fr)
TW (1) TWI302457B (fr)
WO (1) WO2004006919A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004305154A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound
WO2006033287A1 (fr) * 2004-09-21 2006-03-30 Sankyo Company, Limited PRÉPARATION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE ET DE LA GLUTATHIONE
JP4949661B2 (ja) * 2004-09-21 2012-06-13 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
ATE552825T1 (de) 2006-04-26 2012-04-15 Rosemont Pharmaceuticals Ltd Flüssige orale zusammensetzungen
JPWO2015060317A1 (ja) * 2013-10-22 2017-04-06 長谷川　亨 神経変性疾患の検査方法
JP6009050B1 (ja) * 2015-08-21 2016-10-19 国立大学法人東北大学 飲酒による悪酔いまたは二日酔いの軽減または予防剤
WO2020046132A1 (fr) 2018-08-31 2020-03-05 Leiden University Chaperons pharmacologiques pour une thérapie par traitement enzymatique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936723B (en) * 1992-09-14 1995-08-14 Vesta Med Pty Ltd Pharmaceutical preparations for lowering homocysteine levels
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
JP2001520174A (ja) * 1997-10-22 2001-10-30 メルク エンド カムパニー インコーポレーテッド 心血管疾患および脳血管疾患に関するリスクを低下させる併用療法
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
MXPA03004818A (es) * 2000-11-29 2003-09-10 Smithkline Beecham Corp Composicion conteniendo estatinas y calcio para salud cardiovascular mejorada.
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
CN100341509C (zh) 2007-10-10
TWI302457B (en) 2008-11-01
TW200403053A (en) 2004-03-01
HK1077232A1 (en) 2006-02-10
JP2010077162A (ja) 2010-04-08
AU2003281176A1 (en) 2004-02-02
WO2004006919A1 (fr) 2004-01-22
CN1681499A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
WO2009024889A2 (fr) Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
US20060223811A1 (en) Triglycerine depressant composition
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
JP2010077162A (ja) 血中ホモシステイン低下のための医薬組成物
US20150272944A1 (en) Novel triglyceride reducing agent
KR20010093845A (ko) 피브레이트와 세리바스타틴의 복합제제
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US6916849B2 (en) Compositions for improving lipid content in the blood
JP4949661B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
US7037934B2 (en) Blood lipid ameliorant composition
JP4607436B2 (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
JP2005187454A (ja) ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP4611622B2 (ja) 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
US20030216357A1 (en) Compositions for improving lipid content in the blood
JP4896501B2 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
CA2494801A1 (fr) Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase
CA2494916A1 (fr) Composition medicale abaissant le taux de lipides sanguins
JP4454985B2 (ja) 血液脂質を低下させるための医薬組成物
JP2002145774A (ja) 医薬組成物
US20040186163A1 (en) Novel combination
CN100415235C (zh) 含有HMG-CoA还原酶抑制剂的药物组合物
NZ524406A (en) Medicinal compositions containing HMG-CoA reductase inhibitor and ACAT inhibitor
JP2007008923A (ja) フィブラート系薬剤を含有する製剤及びその製造方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead